Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, June 2, 2023
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
[ Fri, Jun 02nd 2023
] - WOPRAI
Thu, June 1, 2023
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
[ Thu, Jun 01st 2023
] - WOPRAI
Yigal Nochomovitz Maintained (ALDX) at Strong Buy with Decreased Target to $25 on, Jun 1st, 2023
Yigal Nochomovitz of Citigroup, Maintained "Aldeyra Therapeutics, Inc." (ALDX) at Strong Buy with Decreased Target from $28 to $25 on, Jun 1st, 2023.
Yigal has made no other calls on ALDX in the last 4 months.
There is 1 other peer that has a rating on ALDX. Out of the 1 peers that are also analyzing ALDX, 0 agree with Yigal's Rating of Hold.
This is the rating of the analyst that currently disagrees with Yigal
- Matthew Caufield of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $15 on, Friday, May 5th, 2023
